Less than two weeks after Pfizer struck a deal with a Chinese drugmaker to gain commercial rights to a GLP-1 drug, the ...
Senators press 11 pharmas for 'any evidence' their Trump drug pricing deals benefit Medicaid savings
Although major pharmaceutical companies have fallen in line with President Donald Trump’s “most favored nation” (MFN) drug pricing agenda, the specifics of their negotiated concessions and the actu | ...
FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression‑free survival and overall survival versus standard ...
Lantern announced partnerships with Novant Health and EmergeOrtho as part of its ongoing collaboration with the North Carolina State Health Plan. Nanox is collaborating with three new partners to ...
The clearance in China comes weeks after Pfizer acquired rights to the therapy. Elsewhere, Alnylam is looking for “novel” cardiovascular targets and investors sold off Helus shares.
Hangzhou Sciwind Biosciences, a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, today announced that China's National Medical ...
Explore how Moderna makes money through its mRNA vaccines, government contracts, and partnerships, and how products like its COVID-19 vaccine drive revenue.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results